Novo Nordisk: FDA approves Fiasp for children
(CercleFinance.com) - The US Food and Drug Administration has approved Novo Nordisk's Fiasp for use as a new mealtime insulin option for children with diabetes, the Danish drugmaker said on Monday.
This means that Fiasp is now available for use in children and adults in three different dosing options: multiple daily injections, continuous subcutaneous insulin infusion pumps and intravenous infusion under supervision by a healthcare professional.
Fiasp is the first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
This means that Fiasp is now available for use in children and adults in three different dosing options: multiple daily injections, continuous subcutaneous insulin infusion pumps and intravenous infusion under supervision by a healthcare professional.
Fiasp is the first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation.
Copyright (c) 2020 CercleFinance.com. All rights reserved.